

Pre-close brief Q2 2026

Gothenburg, Sweden


In line with the ESMA guidelines, we no longer have pre-close calls but are of course available if there is a need for clarifications. The purpose of this pre-close brief is to provide a summary of links and information as support to the public ahead of the next quarterly report.

Financial target 2024-2028

- **>12% adjusted EPS CAGR:** Communicated on slide 11 in the Capital Markets Update on May 15, 2024.

Outlook

- **Short-term:**
 - **Net Sales:** Our latest outlook on net sales for 2026 was provided on page 1 in the Q1 2026 report released on April 21, 2026 [3-5% organic growth excluding Surgical Perfusion]. Please see link to report and transcript below.
- **2024-2028:**
 - **Net Sales:** Our latest outlook on net sales for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.
 - **EBITA margin:** Our latest outlook on EBITA margin for 2024-2028 was provided on slide 14 in the Capital Markets Update on May 15, 2024, see link to presentation and transcript below.



Reports and Transcripts from earnings calls and Capital Markets Update

- Capital Markets Update (May 15, 2024)
 - [Presentation / Transcript](#)
- Q1 2026 (April 21, 2026) – for sequential trend considerations
 - [Report / Transcript](#)
- Q2 2025 (July 18, 2025) – for y-o-y considerations
 - [Report / Transcript](#)

Factors impacting YoY comparative figures

- **Order intake and net sales:** Read more about the order intake and net sales development on page 2 and 6-8 in the Q2 2025 report
- **Margins:** Read more about the margin development on page 3 and 6-8 in the Q2 2025 report
- **Sustainability:** Read more about the Sustainability development on page 5 in the Q1 2026 (sequentially) and Q2 2025 report (YoY)
- **Currency:** Getinge is net long USD versus SEK and EUR. I.e. in general, Getinge benefits from a stronger USD. In 2025, US stood for 40.5% of net sales. More information about Getinge's translation and transaction exposure can be found in note 18 in the [Annual Report 2025](#). A list of the top 20 sales markets in 2025 is found on page 202.
- **Specific events and one offs:** Read more about any specific events and one offs on page 1 and 9 respectively in the notes on page 18-23 in the Q2 2025 report

Latest estimates

- [Consolidated analyst estimates \(Modular Finance\)](#)

Press releases during Q2 2026

- [Getinge news section](#)

Financial calendar

Q2 2026 report	July 17, 2026
Q3 2026 report	October 21, 2026
Q4 and full year 2026 report	January 26, 2027

Contact information:

David Kördel, Head of Investor Relations
Phone: +46 (0)10 335 0077
Email: david.kordel@getinge.com

About Getinge

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile processing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.